List view / Grid view
25 September 2014 | By Roche
Roche announced results from the phase III IMELDA study which showed that the combination of Avastin (bevacizumab) plus Xeloda (capecitabine) chemotherapy as a maintenance treatment following initial induction treatment with Avastin-based therapy resulted in clinically meaningful gains in overall survival...
18 September 2014 | By Roche
Roche announced that it is planning to invest more than half a billion Swiss francs in buildings and infrastructure projects at Kaiseraugst...
17 September 2014 | By Roche
Roche announced that important new data from its established and pipeline medicine portfolio will be presented during the European Society for Medical Oncology (ESMO) 2014 Congress from 26-30 September in Madrid, Spain...
15 September 2014 | By Roche
Roche announced that phase III clinical studies have been initiated for lampalizumab, an investigational drug for geographic atrophy, the advanced form of age-related macular degeneration, a progressive condition which can result in blindness...
8 September 2014 | By Roche
Roche announced that RoACTEMRA (tocilizumab) has received approval from the European Commission for use in patients with severe, active and progressive RA who previously have not been treated with methotrexate...
4 September 2014 | By Roche
Roche announced that Arthur D. Levinson has resigned from the Board of Directors, effective immediately. Arthur D. Levinson made this decision so as to avoid any conflict of interest given his role as Chief Executive Officer at Calico...
2 September 2014 | By Roche
The cobas 6800/8800 Systems offer advanced performance with next generation donor screening assays...
1 September 2014 | By Roche
Roche announced that it has commenced a cash tender offer for all outstanding shares of common stock of InterMune, Inc. at a price of US$74.00 per share...
26 August 2014 | By Roche
Roche and InterMune, Inc. announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction...
15 August 2014 | By Roche
Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone...
6 August 2014 | By Roche
First new treatment option for women in Europe in more than 15 years for most difficult to treat form of ovarian cancer...
5 August 2014 | By Roche
Roche announced that it has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark...
29 July 2014 | By Roche
Roche announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chlorambucil chemotherapy...
28 July 2014 | By AstraZeneca
AstraZeneca announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291...
24 July 2014 | By Roche
Pharmaceutical giant Roche delivers its first-half results for 2014...
